The period for examining the application for authorisation is set at ninety days from the date of receipt of the complete dossier. This period may be extended by ninety days if the Director General of the Agence nationale de sécurité du médicament et des produits de santé considers that additional information, consultations or specific studies are necessary to enable him to reach a decision.